Cocrystal Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.9%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.69next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release | 13 Nov 2026 |
| FY 2026 Annual Earnings Release | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
CDI-988 Phase 1b Norovirus Challenge Study Enrollment Quarterly40.0Target: 40 healthy adults
Cash and Cash Equivalents Quarterly4.8MTarget: Sufficient capital to fund planned Phase 2a influenza trial
CRO Arbitration Claim Refund Quarterly0.0%
Watch Items
- CDI-988 Phase 1b Norovirus Challenge Study Efficacy and Safety DataTrigger: Completion of prevention and treatment cohorts dosing (1,200 mg twice daily for 5 days)Action: Evaluate proof-of-concept efficacy (reduction in clinical symptom incidence and viral shedding) to support Phase 2 planning.
- CC-42344 Phase 2a Influenza A Trial RelaunchTrigger: Securing additional financing or resolving CRO disputeAction: Initiate the new Phase 2a study for oral CC-42344 following previous inconclusive trial conduct issues.
- Going Concern Status and Cash RunwayTrigger: Cash balance falling below $3.0 million without active equity shelf drawdownsAction: Utilize the S-3 shelf registration (up to $150 million) or secure non-dilutive grants to extend operational runway.
Research as of 20 Jun 2026